Survival and functional outcomes in octogenarians with lung cancer.

e20099 Background: The incidence of lung cancer is increasing among octogenarians, yet this population is less likely to receive guideline-concordant cancer-directed therapy. In addition to a higher comborbidity load and reduced physiologic reserve to tolerate treatment, many octogenarians may prioritize quality of life and avoidance of treatment burden over potential survival benefit. Consequently, a better understanding of survival and functional outcomes associated with cancer-directed therapy among octogenarians is needed to inform shared, goal-concordant decision-making. Methods: We conducted a retrospective cohort study using the TriNetX Research Network. Patients diagnosed with lung cancer at age 80 and older were identified and stratified by receipt of cancer-directed therapy (surgery, chemotherapy, immunotherapy, radiation, and/or tyrosine kinase inhibitor therapy) versus no treatment. Patients diagnosed prior to age 80 or without at least one follow-up visit were excluded. Baseline demographics and comorbidities were assessed. To reduce confounding, cohorts were balanced using 1:1 greedy nearest-neighbor propensity score matching based on demographics and comorbidities, with adequate balance defined as a standardized mean difference < 0.1. Post-matching outcomes included new oxygen requirements, utilization of physical or occupational therapy or home health services, and all-cause mortality. Results: After 1:1 propensity score matching, 27,012 patients aged ≥ 80 years with lung cancer were identified. 13,506 elected to receive some form of treatment and 13,506 remained untreated. Within 1 year of diagnosis, treated patients had higher odds of developing a new oxygen requirement compared with untreated patients (OR 1.33, 95% CI 1.19–1.50), but lower odds of physical/occupational therapy or home health utilization (OR 0.73, 95% CI 0.60–0.90). Treated patients also demonstrated lower short-term all-cause mortality (OR 0.79, 95% CI 0.75–0.84). Over longer follow-up (1 day to 5 years), treatment was associated with increased odds of new oxygen requirement (OR 1.38, 95% CI 1.25–1.52), no difference in functional support utilization (OR 0.99, 95% CI 0.84–1.18), and higher all-cause mortality (OR 1.08, 95% CI 1.03–1.13). Conclusions: Treatment in octogenarians with lung cancer improves short-term survival but increases pulmonary morbidity. Importantly, treatment was not associated with improved long-term survival, highlighting the need for individualized treatment decisions that carefully weigh potential short-term benefit against treatment-related morbidity in octogenarians.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Oncology
Published
2026-05-28
DOI
https://doi.org/10.1200/jco.2026.44.16_suppl.e20099
Primary Topic
Lung Cancer Treatments and Mutations
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Survival and functional outcomes in octogenarians with lung cancer.

Melinda Laine Hsu, Matthew M. Mirsky, Zhiting Tang, Jennifer E Murphy et al.
Journal of Clinical Oncology
Lung Cancer Treatments and Mutations
article

Survival and functional outcomes in octogenarians with lung cancer.

Melinda Laine Hsu, Matthew M. Mirsky, Zhiting Tang, Jennifer E Murphy, Lauren Chiec, Mackenzie Deighen, Qian Wang, Afshin Dowlati
article en

Abstract

e20099 Background: The incidence of lung cancer is increasing among octogenarians, yet this population is less likely to receive guideline-concordant cancer-directed therapy. In addition to a higher comborbidity load and reduced physiologic reserve to tolerate treatment, many octogenarians may prioritize quality of life and avoidance of treatment burden over potential survival benefit. Consequently, a better understanding of survival and functional outcomes associated with cancer-directed therapy among octogenarians is needed to inform shared, goal-concordant decision-making. Methods: We conducted a retrospective cohort study using the TriNetX Research Network. Patients diagnosed with lung cancer at age 80 and older were identified and stratified by receipt of cancer-directed therapy (surgery, chemotherapy, immunotherapy, radiation, and/or tyrosine kinase inhibitor therapy) versus no treatment. Patients diagnosed prior to age 80 or without at least one follow-up visit were excluded. Baseline demographics and comorbidities were assessed. To reduce confounding, cohorts were balanced using 1:1 greedy nearest-neighbor propensity score matching based on demographics and comorbidities, with adequate balance defined as a standardized mean difference < 0.1. Post-matching outcomes included new oxygen requirements, utilization of physical or occupational therapy or home health services, and all-cause mortality. Results: After 1:1 propensity score matching, 27,012 patients aged ≥ 80 years with lung cancer were identified. 13,506 elected to receive some form of treatment and 13,506 remained untreated. Within 1 year of diagnosis, treated patients had higher odds of developing a new oxygen requirement compared with untreated patients (OR 1.33, 95% CI 1.19–1.50), but lower odds of physical/occupational therapy or home health utilization (OR 0.73, 95% CI 0.60–0.90). Treated patients also demonstrated lower short-term all-cause mortality (OR 0.79, 95% CI 0.75–0.84). Over longer follow-up (1 day to 5 years), treatment was associated with increased odds of new oxygen requirement (OR 1.38, 95% CI 1.25–1.52), no difference in functional support utilization (OR 0.99, 95% CI 0.84–1.18), and higher all-cause mortality (OR 1.08, 95% CI 1.03–1.13). Conclusions: Treatment in octogenarians with lung cancer improves short-term survival but increases pulmonary morbidity. Importantly, treatment was not associated with improved long-term survival, highlighting the need for individualized treatment decisions that carefully weigh potential short-term benefit against treatment-related morbidity in octogenarians.

Journal of Clinical OncologyVol. 44(16_suppl)
University Hospitals Seidman Cancer Center (US), Center for Clinical Research (United States) (US), University School (US), Case Western Reserve University (US), University of Missouri (US)
Good health and well-being
Openalex Percentile: Top 6%
Lung Cancer Treatments and Mutations
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.